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Abstract:  Cell death associated with mitochondrial dysfunction is common in acute 
neurological disorders and in neurodegenerative diseases. Neuronal apoptosis is regulated 
by multiple proteins, including neuroglobin, a small heme protein of ancient origin. 
Neuroglobin is found in high concentration in some neurons, and its high expression has 
been shown to promote survival of neurons in vitro and to protect brain from damage by 
both stroke and Alzheimer’s disease in vivo. Early studies suggested this protective role 
might arise from the protein’s capacity to bind oxygen or react with nitric oxide. Recent 
data, however, suggests that neither of these functions is likely to be of physiological 
significance. Other studies have shown that neuroglobin reacts very rapidly with 
cytochrome  c released from mitochondria during cell death, thus interfering with the 
intrinsic pathway of apoptosis. Systems level computational modelling suggests that the 
physiological role of neuroglobin is to reset the trigger level for the post-mitochondrial 
execution of apoptosis. An understanding of the mechanism of action of neuroglobin might 
thus provide a rational basis for the design of new drug targets for inhibiting excessive 
neuronal cell death. 
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1. Mitochondrial Pathway of Cell Death–A Target for Neuroprotection 
A number of neuro-pathological conditions are associated with cell death. In ischemic stroke, vessel 
occlusion is followed by glucose and oxygen deprivation. In the umbra, immediately surrounding the 
site of insult, cell death is relatively rapid, whereas in the much larger penumbral region cell death may 
occur over a period of days. Acute death within the umbra is predominantly by necrosis whilst death 
within the ischaemic penumbra is apoptotic. The exact fraction of cells which die from apoptosis, as 
compared with other forms of cell death which are not dependent on caspase activation (e.g., necrosis 
or cell death dependent on autophagy genes), is variable. Irrespective of the morphological features of 
neuronal cell death, it is often associated with mitochondrial dysfunctions [1]. Moreover, 
mitochondrial dysfunctions represent an early event in many neurodegenerative diseases, including 
Alzheimer’s, Parkinson’s, and Huntington’s disease as well as amyotrophic lateral sclerosis [2]. 
Multiple proteins regulate the mitochondrial pathway of cell death, both up-stream and down-stream of 
mitochondria, generating a complex signalling network that functions to buffer limited stress signals 
and maintain homeostasis, protecting post-mitotic neurons from excessive death. The Bcl-2 family of 
proteins regulates events up-stream of mitochondria, weighing the pro-survival signals against the 
stress/damage signals [3]. If the latter prevail, the mitochondrial membrane is permeabilized, which 
leads to deterioration of the bioenergetic functions of mitochondria, overproduction of reactive oxygen 
species (ROS), as well as the release of pro-apoptotic molecules such as cytochrome c from the   
inter-membrane space of the mitochondria into the cytosol. Following its release from the 
mitochondria, cytochrome c binds to Apaf-1, and in the presence of ATP promotes oligomerisation of 
Apaf-1 into the caspase 9-activating platform called the apoptosome (Figure 1). Downstream of 
mitochondria the pathway is regulated not only by the formation of the apoptosome, but also by 
positive and negative feedback loops involving active and inactive caspases and a number of additional 
proteins from the IAP (inhibitor of apoptosis) family, such as X-linked IAP (XIAP) [4] (Figure 1). The 
cooperative action of all these molecules ensures fail-safe mechanisms, i.e., cells only commit to death 
if stress signal overcomes all the protective measures, but try to recover if only a portion of   
pro-survival factors is affected. Identification of new regulatory proteins expressed in neurons may 
allow for specific intervention in this process, by means of tipping the balance in favour of cell 
survival, and represents a promising avenue for neuroprotection. 
2. Neuroglobin Is an Evolutionarily Conserved Neuroprotective Protein 
Although the presence of globin protein in the nerves of invertebrates was reported as long ago as 
1872 [5] it was not until 2000 that Burmester et al. [6] convincingly showed the presence of such a 
protein in the neural tissues of the mouse, leading to the designation – neuroglobin. Neuroglobin has 
since been thoroughly characterised and shown to be a 17 kDa molecular weight, single peptide 
member of the globin super family, exhibiting the same basic structure as the other vertebrate 
members with a 3 on 3 globin fold, binding a single heme group [7-9]. The main structural difference 
between neuroglobin and the other members of the family is the presence of a predominantly   
bis-histidine, 6 co-ordinate, structure at the heme binding site. This form of the protein is in Int. J. Mol. Sci. 2010, 11                 
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equilibrium with a very small fraction of a mono-histidine, 5 coordinate form which is reactive with all 
the gaseous ligands normally associated with globin function [10-13].  
Figure 1. The intrinsic pathway of apoptosis.  Mitochondrial pathway of cell death is 
triggered by a number of internal and external stimuli, and heavily regulated by proteins 
both up-stream and down-stream of mitochondria. Pre-mitochondrial events that regulate 
mitochondrial outer membrane permeabilisation (MOMP) in neurons include increase in 
Ca
2+ and reactive oxygen species (ROS) levels. MOMP is tightly regulated by the   
multi-protein Bcl-2 family, which consists of both anti- and pro-apoptotic members. 
Down-stream of mitochondria, the pathway is regulated by the low-probability event of 
apoptosome assembly, as well as positive and negative feedback loops involving caspase 3 
and 9, and inhibitor of apoptosis proteins such as XIAP. Cytochrome c is a key protein, 
initiating apoptosome assembly and activation of caspase cascade. Neuroglobin binding to 
and reduction of cytochrome c interferes with the mitochondrial pathway of apoptosis 
immediately down-stream of mitochondria, affecting all types of up-stream stress signals. 
Lines in red represent inhibitory effects. 
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Neuroglobin shares little amino acid sequence homology with myoglobin, haemoglobin and 
cytoglobin (Figure 2a) but its amino acid sequence is highly conserved between species (Figures 2b 
and c). Phylogenetic analysis indicates a very ancient lineage for this protein, with the other vertebrate 
globins having diverged from neuroglobin more than 600M years ago [14]. Although neuroglobin has 
been widely reported as being expressed in brain neurons, its detailed distribution in the mouse brain 
has only recently been published [17]. From these studies it is clear that neuroglobin is present at high 
concentration in relatively few areas of the mouse brain, including piriform cortex, amygdale, 
hypothalamus, arcuate nucleus, habenular nuclei, laterodorsal tegmental nucleus, pedunculopontine 
tegmental nucleus, locus coeruleus, nucleus of the solitary tract and the spinal trigeminal nucleus, and 
is expressed at highest concentrations in orexin stimulated neurons [17]. The level of neuroglobin in 
the human brain has also recently been reported [18]. The highest levels were found in the cerebral 
cortex and caudatoputamen, and intermediate levels were found in the cerebellum, substantia nigra and 
medulla, a distribution similar to that previously reported for neuroglobin mRNA [6]. 
Figure 2. Neuroglobin shares little amino acid sequence homology with other family 
members and is highly conserved throughout species. Protein alignment of neuroglobin 
and (a) other human globin family members or (b) showing homology between species. 
Residues marked in red match the consensus, residues in blue are weakly conserved. 
Protein alignments were performed using MultAlin ver 5.4.1 [15]. (c) Phylogenetic tree 
representing conservation of neuroglobin throughout evolution. Phylogenetic analysis was 
performed using Phylogeny.fr. [16]. 
(a) 
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Figure 2. Cont. 
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An ancient origin and extreme conservation of neuroglobin’s amino acid sequence, combined with 
its neuronal localization [6,17], has been taken as indicative of a very specific and crucial role for this 
protein. Several studies have associated genetic polymorphisms within the human neuroglobin gene 
with neuroprotection [19-21], and decreased expression of neuroglobin in older people, in women, or 
associated with single nucleotide polymorphism has been linked to increased risk of Alzheimer’s 
disease [19]. Together with the population-based genetic association studies, and observations that 
some forms of neuronal injury are associated with an increased expression of neuroglobin [12], more 
direct evidence has also been mounting to support the role of neuroglobin in protecting cells from a 
variety of apoptotic challenges. In cultured cells, ectopic over-expression of neuroglobin has been 
shown to protect against amyloid beta-hydrogen peroxide-, paraquat-, and HA14-1 (the BH3 mimetic)-
induced cell death, as well as from oxygen and glucose deprivation [22-27]. The neuroprotective role 
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of endogenous neuroglobin has been also supported by its knock-down in vitro, which renders cortical 
neuronal cultures more susceptible to hypoxia [19], and decreasing viability of neuroblastoma cells 
under oxidative stress [28]. Although some questions have been raised concerning the capacity of 
neuroglobin to provide general protection to neurons in vivo [29], other in vivo studies support the 
neuroprotective role of this protein. In neuroglobin-overexpressing transgenic animals the size of 
cerebral infarct is drastically reduced [30,31]. Similarly, intra-cerebral administration of neuroglobin-
expressing adeno-associated virus vector reduced infarct size in rats after focal cerebral ischemia, with 
opposite effects observed following knock-down of endogenous neuroglobin in rat brains [32]. 
Contradictions in data derived from in vivo experiments almost certainly arises, at least in major part, 
from differences in the nature, severity, and duration of challenge used in the various studies. Any 
proposed mechanism of action of neuroglobin, in neurons, thus must consider not only its capacity to 
provide at least a level of protection to many cell types in the brain but also account for its very non-
uniform distribution in the brain.  
3. Proposed Mechanisms for Neuroglobin-Mediated Neuroprotection 
Increased expression of neuroglobin has been shown to protect against stroke and Alzheimer’s 
disease in vivo, and to promote neural survival after oxygen or glucose deprivation, or following 
oxidative stress. Consequently, a considerable effort has been put into dissecting the molecular 
mechanisms of neuroglobin’s action under these conditions. Much of the initial work focussed on the 
myoglobin-like reactivity of the approx 0.1% of the five co-ordinated species present in neuroglobin at 
equilibrium  in vitro. These studies proposed that neuroglobin might protect cells by supporting 
mitochondrial oxidative respiration during time of challenge [33]. Unfortunately, most of these studies 
relied on the early reports of high, myoglobin like, oxygen affinity of neuroglobin, and ignored the 
potential for oxygenated neurolgobin to undergo autoxidation [11]. More recent studies, in which 
autoxidation was suppressed, indicate that neuroglobin’s affinity for oxygen is considerably   
lower [34]. In fact, under normal physiological conditions, neuroglobin is expected to be only partially 
saturated with oxygen [34]. These findings, taken together with the relatively low levels of 
neuroglobin (as compared to myoglobin), even at the sites of its highest expression, have now lead to 
an abandoning of this hypothesis [35]. 
Another myoglobin-like reactivity expressed by neuroglobin, namely reaction with nitric oxide 
(NO), lead to the suggestion that neuroglobin might play a role in NO homeostasis or scavenging 
[12,36]. The activity of neuronal NO synthases increases after ischemic and traumatic brain injury 
[37], and the resulting excess NO can rapidly impair mitochondrial functions, leading to mitochondrial 
permeability, activation of caspase 3 and neuronal cell death [38]. Hence, NO-scavenging activity of 
neuroglobin could provide neuroprotection. Since this initial suggestion, further studies have identified 
a rich and complex chemistry for the reactivity of both ferric and ferrous forms of neuroglobin with a 
range of nitrogen compounds in vitro. Apart from reacting with NO, neuroglobin is also involved in 
nitrite and peroxynitrite chemistry [39] (for which it has unusual reactivity in that it does not react via 
a ferryl intermediate [40]). However, neuroglobin’s role in detoxification of NO, as envisioned earlier, 
has been drawn into question by the findings that it is not significantly more reactive than hemoglobin 
or myoglobin [13]. Furthermore, it has been highlighted that any useful biological reactivity with NO Int. J. Mol. Sci. 2010, 11                 
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would require the presence of a very effective re-reducing system. Despite many attempts to identify 
such a system, non has been identified [12,41-43].  
Considering the lack of mechanistic explanation of neuroglobin’s neuroprotective effects, further 
attempts have been recently made to provide a more detailed understanding of its physiological 
functions. Khan and co-authors have recently suggested that neuroglobin inhibits Pak1 kinase and 
interacts with RhoGDI and RhoGTPase family members, inhibiting propagation of hypoxia-induced 
death signal in a form of cytoskeletal reorganisation and mitochondrial aggregation at the sites of raft 
membrane microdomains [44]. This newly-identified and neuroglobin-regulated death signalling 
module is formed not only during hypoxia, but also during amyloid beta- and NMDA-induced 
neuronal cell death [45]. 
4. Reactivity with Cytochrome C 
During studies of the redox activities of neuroglobin it was found that very rapid reaction occurs 
between ferrous neuroglobin and ferric cytochrome c. The high rate of intermolecular electron 
exchange (approx 2,000 s
-1) is in the range reported for other biologically significant protein-protein 
redox reactions such as cytochrome c reduction of cytochrome c oxidase [46] or the reduction of 
hemoglobin or cytochrome c by cytochrome b5 [47,48]. This reaction appears to be composed of two 
steps, namely complex formation followed by electron exchange [49,50]. How might this reaction be 
of importance in neuroprotection? During the activation of the intrinsic pathway of apoptosis or 
programmed cell death cytochrome c is released into the cytosol, following mitochondrial outer 
membrane permeabilisation (MOMP) (Figure 1). This process is induced by a plethora of stress signals 
experienced by neurons, including oxygen or glucose deprivation, increased levels of calcium or ROS, 
or accumulation of amyloid beta peptide (Figure 1) [1]. Release of cytochrome c into the cytosol 
would then bring neuroglobin and cytochrome c into contact. This process would be significantly 
enhanced by the electrostatic interactions between the two proteins, as cytochrome c is an unusually 
basic protein (pI = 10.2) whilst neuroglobin is an unusually acidic protein (pI = 4.6). Thus, at neurtral 
pH neuroglobin would be highly negatively charged whilst cytochrome c would be very positively 
charged. The finding that neuroglobin reacts very rapidly with cytochrome c lead to the hypothesis that 
neuroprotection by neuroglobin arises from its intervention in the intrinsic pathway of apoptosis 
following the release of cytochrome c into the cytosol [51].  
5. Experimental Evidence for Cytochrome c-Neuroglobin Interaction 
In the absence of direct structural determinations of the complex formed between cytochrome c and 
neuroglobin, computational methods have been used to identify putative structures for this complex. 
Application of soft docking algorithms to this problem has predicted the production of an ensemble of 
closely related structures, which share a common binding site but exhibit a small degree of slippage 
across this binding interface [50] (Figure 3). When other potential heme binding partners, such as 
myoglobin, were studied in the same system no such specific docking was observed. Close 
examination of the lowest energy complex has allowed the identification of amino acids likely to be 
involved in the docking process. In particular Lys25 and Lys72 appear to play a significant role in the 
interface between neuroglobin and cytochrome c (Figure 3). It is interesting to note that these two Int. J. Mol. Sci. 2010, 11                 
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amino acids have previously been identified as key residues in the interaction of cytochrome c with 
Apaf-1 [52-55] – the major cytosolic protein involved in apoptosome assembly. Experimental evidence 
for the formation of a cytochrome c-neuroglobin complex in solution has been obtained using both 
NMR and surface plasmon resonance studies [50]. These experiments indicate the formation of a 
weakly bound complex (K ~ 100M) which is sensitive to both temperature and ionic strength. 
Figure 3. Cytochrome c binding to neuroglobin. (a) Shows the ensemble of complexes 
calculated from soft docking calculations. The centres of mass of the docked cytochrome c 
molecules are indicated by the small spheres. (b) Shows the structure of the lowest energy 
docked complex with neuroglobin in blue and cytochrome c in green. 
 
The ability of neuroglobin to interact with cytochrome c and hence interfere with the process of 
apoptosis, via inhibition of apoptosome assembly, has also been studied more directly. Using cell 
lysates devoid of mitochondria but containing Apaf-1, it has been demonstrated that although 
neuroglobin itself has no capacity to affect apoptosome assembly, in its presence the pro-apoptotic 
activity of cytochrome c is lost [26]. These biochemical findings have been further supported by 
cellular studies in human neuroblastoma SH-SY5Y cells treated with the BH3 mimetic (Bcl-2 
inhibitor), HA14-1. In response to HA14-1, SH-SY5Y cells undergo the mitochondrial pathway of 
apoptosis, associated with the loss of mitochondrial transmembrane potential and activation of initiator 
caspase 9. This specifically-induced mitochondrial pathway of apoptosis is significantly blocked by 
ectopically-overexpressed neuroglobin, with the extent to which neuroglobin increases survival of 
HA14-1-treated cells depending on the strength of stress. While micromolar levels of neuroglobin are 
capable of nearly completely blocking cell death induced by a low-level BH3 mimetic-induced stress 
signal, rapid apoptosis triggered by high-level stress is blocked only partially. Considering the 
complexity of the apoptotic network, analysis of the role of neuroglobin in regulation of apoptosis, 
depending on the concentration of this protein as well as varying stress, is not easily accessible 
experimentally.  
Recent developments in the field of computational systems level biology of apoptotic pathways 
open new doors to the modeling of cellular responses and their dependence on protein concentration 
and type/strength of stress. Using Monte Carlo computational modeling of apoptotic signaling, based Int. J. Mol. Sci. 2010, 11                 
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on measured reaction rate constants, where diffusion and reaction of signaling molecules are simulated 
at an individual molecular level, it is possible to explicitly simulate molecular interactions and model 
spatial heterogeneity such as the localization of pro- and anti-apoptotic proteins on mitochondrial 
membranes or formation of multi-protein apoptosome complexes [56]. Models based on ordinary 
differential equations (ODEs) which have previously been employed [57] cannot simulate such 
important details of apoptotic signaling. More importantly, ODE-based models cannot capture cell-to-
cell stochastic variability in apoptotic signaling that arise solely due to the inherent stochastic nature of 
chemical reactions. Careful validation of the key findings of such Monte Carlo computational models, 
such as the time scale of apoptosis, all-or-none caspase activation with large cell-to-cell variability, 
and the post-mitochondrial origin of cell-to-cell variability in the execution of the mitochondrial 
pathway of apoptosis, has allowed the application of such models to the study of the impact of 
neuroglobin on apoptotic networks in more detail [26,56].  
These studies indicate that, thanks to its extremely rapid redox reaction with cytochrome c, 
neuroglobin can inhibit activation of caspases, associated with the inhibition of the low probability 
event of apoptosome formation, and that the activation of executioner caspase 3 is very sensitive to the 
ratio of neuroglobin and cytochrome c  concentrations  [26].  As the concentration of cytosolic 
cytochrome c increases, which mimics a situation observed in highly stressed cells, an increasingly 
higher concentration of neuroglobin is needed to block activation of caspases. The required protective 
concentration of neuroglobin depends on the increases in cytochrome c concentrations in a non-linear 
manner [26]. Using the same computational approach it has been shown that a higher level of cytosolic 
neuroglobin is needed to completely abolish apoptotic activation in the absence of redox reaction 
between cytochrome c and neuroglobin [26]. In the future, extended model calculations will help to 
elucidate the co-operation between neuroglobin and other anti-apoptotic proteins that act down-stream 
of mitochondria, for example the inhibitor of apoptosis (IAP) proteins.  
6. Hypothesis: A Co-Ordinating Role for Neuroglobin 
The reaction of neuroglobin with cytochrome c might well have multiple effects on apoptosis 
(Figure 4). In terms of direct action on apoptotic signaling, the reaction of ferrous neuroglobin with 
ferric cytochrome c, released from the mitochondria, would produce ferrous cytochrome c. This 
reaction would thus convert pro-apoptotic ferric cytochrome c into non-apoptotic ferrous cytochrome c 
[58-60], stopping apoptosome formation and hence halting apoptosis. During the normal process of 
activation of the intrinsic pathway of apoptosis cytochrome c released from mitochondria suppresses 
the auto-inhibition of calcium release from type 1 IP3 receptors in the ER [61]. This initiates a feed 
forward amplification cycle, as raised calcium levels induce other mitochondria to release further 
amounts of cytochrome c, and so an apoptotic avalanche is created. In the presence of neuroglobin the 
initially released cytochrome c is sequestered by the neuroglobin and the apoptotic avalanche avoided. 
In vivo support for such a function of neuroglobin in suppression of cytosolic calcium levels during 
apoptosis can be found in the work of Duong et al. [62] and Liu et al. [63]. These authors showed that 
apoptotic challenge of SH-SY5Y cells and cultured transgenic mouse cortical neurons over-expressing 
neuroglobin lead to suppression of cytosolic clalcium levels whilst maintaining mitochondrial 
membrane potential and cytosolic ATP concentrations. Further more on reaction with ferric Int. J. Mol. Sci. 2010, 11                 
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cytochrome  c ferrous neuroglobin is converted to ferric neuroglobin. Ferric neuroglobin has been 
identified as a potent inhibitor of GPCR and hence IP3 production [64]. The reaction of ferrous 
neuroglobin with ferric cytochrome c thus produces another factor responsible for the suppression of 
increased cytosolic calcium concentration and suppresses apoptosis. The levels of neuroglobin 
indicated as protective by computational studies are consistent with those found in nerve cells, and 
may have the capacity to protect the cells from mild challenge such as those arising from calcium 
fluctuations encountered during normal nerve function. In support of this hypothesis, neuroglobin is 
found at high concentrations in neurons stimulated with orexin, an excitatory neuropeptide which 
increases intracellular Ca
2+ concentration in neurons together with amyloid peptide, both pro-apoptotic 
stimuli [65]. 
Figure 4. A co-ordinating role for neuroglobin. The diagram shows the three actions of 
neuroglobin: (1) in suppressing apoptosis by binding and reducing cytochrome c released 
from mitochondria, (2) in inhibiting the production of IP3 by GPCR and (3) maintaining 
the auto-feedback loop, which limits the release of calcium from endoplasmic reticulum 
(ER) via type 2 IP3 receptors by binding cytochrome c. 
 
 
7. Neuroglobin in Brain Tumours: Dr Jekyll or Mr Hyde? 
The strategy of blocking apoptosis operates also in cancer cells, which by virtue of over-expression 
of anti-apoptotic proteins survive despite being subjected to harsh environmental conditions or 
intracellular pro-apoptotic signalling [66]. If neuroglobin-mediated protection from cell death is of 
physiological relevance, one could expect that cancer cells will also hijack this mechanism to advance 
their survival. In agreement with this hypothesis, a recent particular study has shown that neuroglobin 
is up-regulated in hypoxic microregions of glioblastoma tumour xenografts [67].  
Brain tumours are usually resistant to conventional chemotherapeutics that trigger apoptosis   
up-stream of mitochondria, but remain sensitive to post-mitochondrial induction of apoptosis [68]. 
This indicates that despite over-expression of anti-apoptotic proteins that regulate MOMP, apoptotic 
signalling down-stream of mitochondria remains functional in these cancer cells. An increased 
expression of Apaf-1 has been detected in high-grade astrocytomas, medulloblastomas, and gliomas as Int. J. Mol. Sci. 2010, 11                 
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compared to adjacent normal neural tissue [68]. This leads to hyperactivation of post-mitochondrial 
events of the intrinsic pathway of apoptosis, as illustrated by the fact that glioblastoma and 
medulloblastoma cell lines are more sensitive to the impact of cytosolic cytochrome c than are normal 
neural cells [68]. It can be thus hypothesized that not only increased Apaf-1 expression, but also 
decreased expression of neuroglobin, could contribute to the high sensitivity of brain tumours to post-
mitochondrial induction of apoptosis. This has not yet been investigated, but analysis of gene profiling 
data from Sun et al. [69], accessed through the Oncomine Gene Profiling Database, demonstrates a 
statistically significant decrease in neuroglobin mRNA levels in glioblastoma, oligonendroglioma and 
astrocytoma as compared with brain from epilepsy patients. Undoubtedly further studies are required 
to dissect the role of neuroglobin in tumorigenesis and sensitivity to chemotherapy, and to identify 
potential of interfering in neuroglobin-cytochrome c interaction in cancer cells for therapeutic 
purposes. 
8. Surviving the Release of Cytochrome c: Neuroglobin as a Drug Target 
Delayed or aborted apoptosis can allow survival of cells under stress. Whether blocking apoptosis 
can rescue neurons and allow their recovery from the loss of mitochondrial transmembrane potential 
may well depend on the type and strength of stress signal. Several lines of evidence suggest, however, 
that survival of neurons can be significantly enhanced providing formation of apoptosome/activation 
of caspases is blocked [70]. Therefore, blocking immediate post-mitochondrial events, such as 
cytochrome  c-mediated formation of the apoptosome, could be a widely applicable target for 
neuroprotection. In the future efforts will be directed towards understanding the structural 
requirements for neuroglobin-cytochrome c interactions, and the design of neuroglobin mimetics that 
will render cytochrome c apoptotically inactive.  
9. Conclusions 
Neuroglobin is an evolutionarily highly conserved protein localized in brain neurons where it 
protects from a variety of insults, such as oxidative stress or amyloid beta accumulation. The 
neuroprotective role of neuroglobin has been shown both in vitro and in vivo, and its decreased 
expression has been associated with increased risk of Alzheimer’s disease. The quest for understanding 
how neuroglobin interferes with neuronal cell death has led to several hypotheses. Recent studies 
indicate that neuroglobin can interfere with propagation of cell death signaling mediated by 
RhoGTPases, as well as bind to ferric cytochrome c and inhibit its apoptotic activity. Neuroglobin 
emerges as a critical player that regulates immediate post-mitochondrial events in the intrinsic pathway 
of apoptosis, opening new avenues for therapeutic interventions in numerous neurological disorders. 
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